Overcoming intrinsic and acquired cetuximab resistance: an in vitro study on the potential of afatinib in HNSCC cell lines

被引：0
|
作者：
De Pauw, Ines
Wouters, An
Van den Bossche, Jolien
Deschoolmeester, Vanessa
Pauwels, Patrick
Vermorken, Jan B.
Peeters, Marc
Lardon, Filip
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4102
引用
收藏
页数：2
相关论文
共 50 条
  • [41] ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS
    Janjigian, Y. Y.
    Smit, E. F.
    Horn, L.
    Groen, H. J. M.
    Camidge, D. R.
    Gettinger, S.
    Fu, Y.
    Denis, L. J.
    Miller, V.
    Pao, W.
    ANNALS OF ONCOLOGY, 2012, 23 : 401 - 401
  • [42] Mechanisms of methotrexate resistance in osteosarcoma cell lines and strategies for overcoming this resistance
    Wang, Jianjun
    Li, Guojun
    ONCOLOGY LETTERS, 2015, 9 (02) : 940 - 944
  • [43] Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational Applications
    Zhang, Jihong
    Stevens, Malcolm F. G.
    Laughton, Charles A.
    Madhusudan, Srinivasan
    Bradshaw, Tracey D.
    ONCOLOGY, 2010, 78 (02) : 103 - 114
  • [44] Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications
    Bradshaw, T. D.
    Zhang, J.
    Stevens, M. F. G.
    Laughton, C. A.
    Madhusudan, S.
    Kirschmeier, P.
    EJC SUPPLEMENTS, 2008, 6 (12): : 153 - 153
  • [45] ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
    Johnson, Radia M.
    Qu, Xueping
    Lin, Chu-Fang
    Huw, Ling-Yuh
    Venkatanarayan, Avinashnarayan
    Sokol, Ethan
    Ou, Fang-Shu
    Ihuegbu, Nnamdi
    Zill, Oliver A.
    Kabbarah, Omar
    Wang, Lisa
    Bourgon, Richard
    de Sousa e Melo, Felipe
    Bolen, Chris
    Daemen, Anneleen
    Venook, Alan P.
    Innocenti, Federico
    Lenz, Heinz-Josef
    Bais, Carlos
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [46] ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
    Radia M. Johnson
    Xueping Qu
    Chu-Fang Lin
    Ling-Yuh Huw
    Avinashnarayan Venkatanarayan
    Ethan Sokol
    Fang-Shu Ou
    Nnamdi Ihuegbu
    Oliver A. Zill
    Omar Kabbarah
    Lisa Wang
    Richard Bourgon
    Felipe de Sousa e Melo
    Chris Bolen
    Anneleen Daemen
    Alan P. Venook
    Federico Innocenti
    Heinz-Josef Lenz
    Carlos Bais
    Nature Communications, 13
  • [47] Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
    Iida, Mari
    Brand, Toni M.
    Starr, Megan M.
    Huppert, Evan J.
    Luthar, Neha
    Bahrar, Harsh
    Coan, John P.
    Pearson, Hannah E.
    Salgia, Ravi
    Wheeler, Deric L.
    MOLECULAR CANCER, 2014, 13
  • [48] Overcoming acquired resistance to cetuximab by dual targeting of HER family members using antibody based therapy
    Iida, Mari
    Brand, Toni M.
    Starr, Megan M.
    Luthar, Neha
    Wleklinski, Matthew J.
    Wheeler, Deric L.
    CANCER RESEARCH, 2013, 73 (08)
  • [49] Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
    Mari Iida
    Toni M Brand
    Megan M Starr
    Evan J Huppert
    Neha Luthar
    Harsh Bahrar
    John P Coan
    Hannah E Pearson
    Ravi Salgia
    Deric L Wheeler
    Molecular Cancer, 13
  • [50] Potential role of dose escalation in overcoming acquired resistance to cabozantinib in metastatic renal cell carcinoma (mRCC).
    Sharma, Akanksha
    Elias, Roy
    Christie, Alana
    Williams, Noelle S.
    Pedrosa, Ivan
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345